
|Videos|October 3, 2020
HER2-targeted Therapy: Routes of Administration
Author(s)Staff
Evaluating the benefits of the subQ vs IV formulation of the trastuzumab-pertuzumab combination for the management of HER2+ breast cancer and examining the potential use of at-home administration.
Advertisement
Evaluating the benefits of the subQ vs IV formulation of the trastuzumab-pertuzumab combination for the management of HER2+ breast cancer and examining the potential use of at-home administration.
Advertisement
Latest CME
Advertisement
Advertisement


















































































